

CATALYST PHARMACEUTICAL PARTNERS, INC.

Form 3

November 13, 2012

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *			2. Date of Event Requiring Statement	3. Issuer Name <b>and</b> Ticker or Trading Symbol	
Â BIOMARIN PHARMACEUTICAL INC			(Month/Day/Year) 11/05/2012	CATALYST PHARMACEUTICAL PARTNERS, INC. [CPRX]	
(Last)	(First)	(Middle)	4. Relationship of Reporting Person(s) to Issuer		5. If Amendment, Date Original Filed(Month/Day/Year)
105 DIGITAL DRIVE			(Check all applicable)		6. Individual or Joint/Group Filing(Check Applicable Line)
(Street)			___ Director <input checked="" type="checkbox"/> 10% Owner		___X_ Form filed by One Reporting Person
NOVATO,Â CAÂ 94949			___ Officer    ___ Other (give title below)    (specify below)		___ Form filed by More than One Reporting Person
(City)	(State)	(Zip)			

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
------------------------------------	----------------------------------------------------------	-------------------------------------------------------------------	----------------------------------------------------------

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable    Expiration Date	Title                      Amount or Number of Shares			

Convertible Promissory Note and Note Purchase Agreement	12/08/2012 <sup>(1)</sup>	12/08/2012	Common Stock	6,666,667	\$ 0.75 <sup>(2)</sup>	D	Â
------------------------------------------------------------------	---------------------------	------------	-----------------	-----------	------------------------	---	---

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
BIOMARIN PHARMACEUTICAL INC 105 DIGITAL DRIVE NOVATO, CA 94949	Â	Â X	Â	Â

## Signatures

BioMarin Pharmaceutical Inc., By: /s/ G. Eric Davis, Name: G. Eric Davis, Title: Senior Vice President, General Counsel and Secretary 11/12/2012

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The Convertible Note will be automatically converted into shares of Common Stock on December 8, 2012 (the "Conversion Date"), which is the 30th day after announcement by Catalyst Pharmaceutical Partners, Inc. (the "Issuer") of top-line data from the Issuer's Phase II(b) clinical trial evaluating the use of CPP-109 (the Issuer's formulation of vigabatrin, a GABA aminotransferase inhibitor) for the treatment of cocaine addiction.

(2) The number of shares issuable upon conversion of the Convertible Note is calculated by dividing the aggregate principal amount of the note, \$5,000,000 by the "Conversion Price" in effect on the Conversion Date. The Conversion Price is the dollar weighted average price of the Common Stock for the 15 business day period prior to the Conversion Date, multiplied by 0.9; provided, however, that the Conversion price shall not be less than \$0.75 per share or more than \$2.50 per share. Accordingly, the number of shares beneficially owned by BioMarin Pharmaceutical Inc. may fluctuate from time to time based on the underlying trading price and volume of the Issuer's Common Stock. The number of shares reflected in the table were calculated based on the Conversion Price of \$0.75 in effect at the close of trading on November 9, 2012.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.